Galmed Pharmaceuticals EOCN
NASDAQ EOCN
$3.49 -0.05 (-1.41%)
As of: Sep 30, 2026 · 2:30 PM EDT

Galmed Pharmaceuticals (EOCN) Current Deferred Revenue (2016 - 2018)

Updated

Galmed Pharmaceuticals' Current Deferred Revenue came in at $270,000 for Q1 2018, down 75.1% from $1.09 million a year earlier and down 49.8% from the prior quarter.

Analysis

Galmed Pharmaceuticals (EOCN) Current Deferred Revenue (2016 - 2018) Analysis & Trends

At the end of FY2017, Galmed Pharmaceuticals' Current Deferred Revenue was $538,000, down 50.8% from FY2016.

  • Going back by year, Current Deferred Revenue was $1.09 million in FY2016.
  • Year-over-year, Current Deferred Revenue has declined for three consecutive quarters.
  • Business Quant data shows EOCN's Current Deferred Revenue at $538,000 (Q4 2017), $811,000 (Q3 2017) and $1.09 million (Q2 2017) in the three quarters before Q1 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Galmed Pharmaceuticals 403,744.91 403,744.91 -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2018 270,000.00
Dec 31, 2017 538,000.00
Sep 30, 2017 811,000.00
Jun 30, 2017 1.09 Mn
Mar 31, 2017 1.09 Mn
Dec 31, 2016 1.09 Mn
Sep 30, 2016 1.05 Mn
API Access

Galmed Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=EOCN&period=max&api_key=YOUR_API_KEY